License plates of MIT
Custom plates display expressions of scholarship, creativity, and MIT pride among Institute affiliates.
Custom plates display expressions of scholarship, creativity, and MIT pride among Institute affiliates.
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.
With the new technique, MIT researchers hope to identify mutations that could be targeted with new cancer therapies.
By analyzing bacterial data, researchers have discovered thousands of rare new CRISPR systems that have a range of functions and could enable gene editing, diagnostics, and more.
New research finds RNA-guided enzymes called Fanzors are widespread among eukaryotic organisms.
A new approach for identifying significant differences in gene use between closely-related species provides insights into human evolution.
The first RNA-guided DNA-cutting enzyme found in eukaryotes, Fanzor could one day be harnessed to edit DNA more precisely than CRISPR/Cas systems.
With the new method, scientists can explore many cancer mutations whose roles are unknown, helping them develop new drugs that target those mutations.
The new diagnostic, which is based on analysis of urine samples, could also be designed to reveal whether a tumor has metastasized.
The global health care company Sanofi is providing $25 million to advance RNA research.
Using these RNA-delivery particles, researchers hope to develop new treatments for cystic fibrosis and other lung diseases.
Using this approach, researchers hope to deliver therapeutic RNA molecules selectively to cancer cells or other target cells.
Known as PASTE, the technique holds potential for treating a variety of diseases caused by faulty genes.
Researchers harness new pooled, image-based screening method to probe the functions of over 5,000 essential genes in human cells.
Researchers have developed a technique that could help fine-tune the production of monoclonal antibodies and other useful proteins.